Cannabinoid API Manufacturing Benefits and Calculator
The Profit Opportunity is Immense
KEY STAT: Cannabinoid API projects can carry different quality, documentation, and commercial requirements than crude-extract operations; project economics should be evaluated for the specific product and market.
With the anticipated rescheduling of cannabis to Schedule III by the DEA, state-licensed cannabis extraction and processing labs have an incredible ROI opportunity to capitalize upon by pivoting into pharmaceutical cannabinoid API manufacturing. Here are the key definitions, reasons and benefits for making this strategic transition:
What is an API?
The active ingredient in a pharmaceutical drug is called an active pharmaceutical ingredient (API). An example of an API is the acetaminophen contained in a pain relief tablet such as Tylenol. Active ingredients are the substances in drugs that are responsible for the beneficial health effects experienced by consumers. For cannabis-isolate applications, target purity may be ~99%+ (e.g., THCA), depending on product specifications and process.
What do APIs have to do with cannabis extraction?
Schedule III changes the controlled-substance classification for qualifying activity, but it does not itself grant product authorization, eliminate manufacturing or registration requirements, or authorize international distribution.
Other cannabis-derived APIs, such as Cannabidiol (CBD) also constitute an incredible ROI opportunity with CBD API selling in Europe for 5,900 to 9,000 EUROS per kilogram. (Source: https://www.statista.com/statistics/1375642/europe-price-of-cbd-api-per-kg/). Due to its current scarcity, Tetrahydrocannabinol THC API is anticipated to be much more expensive, and therefore immensely lucrative to pharmaceutical API manufacturers.
In the United States, both THC and CBD have been approved by the FDA for certain pharmaceutical applications. THC (dronabinol) is the active ingredient in the approved drug products, Marinol capsules (and generics) and Syndros oral solution. CBD is the active ingredient in the approved drug product, Epidiolex. Neither THC nor CBD are approved by the FDA as food or dietary supplement ingredients. FDA approval depends on the specific drug product and submission; DEA scheduling is a separate question.
Converting to pharmaceutical API manufacturing may open commercial opportunities for teams that satisfy the product-specific, quality, licensing, and jurisdictional requirements applicable to their intended markets.
PRO TIP What is C₂₁H₃₀O₂ Δ-9 Tetrahydrocannabinol (THC)?
That's the fancy pharmaceutical name for Delta-9 THC, the main psychoactive component of the cannabis plant, which may be manufactured synthetically or derived from botanical cannabis.
State-legal cannabis extraction labs in the United States have been extracting THC and other cannabinoids from botanical cannabis for over a decade.
TAKEAWAY: A Cannabinoid API is born!!
*Prodigy has turnkey life science lab equipment solutions to support ~99%+ pure cannabis isolate (e.g., THCA) projects. Our team of extraction and compliance experts have been advising and equipping cannabis extraction labs for their transition to pharmaceutical API manufacturing via GMP compliance, state licensing, and DEA and FDA registration to capitalize on this momentous opportunity. Cannabinoid API Calculator Crude Cannabis Oil to C₂₁H₃₀O₂ Δ-9 Tetrahydrocannabinol (THC)
As of Aug 2024: Cost of 1 lb of cannabis trim containing approx. 10% THCA/THC by volume by weight is $10 – $15 (confirmed for California and Oklahoma). Delta-9 THC API market rates in EU pharmaceutical industry range $20,000 – $45,000 while CBD API is $5,000 – $9,000 (estimates do your own research).
Steps to Become an FDA Compliant, State Licensed, and DEA Registered Pharmaceutical Manufacturing Facility LET'S GET STARTED Transition your lab to FDA cGMP pharmaceutical compliance and DEA registration! CONTACT US More Reasons to Upgrade to Pharmacuetical Cannabinoid API Manufacturing Enhanced Credibility and Consumer Trust
Building Trust with Consumers and Partners:
Producing pharmaceutical-grade cannabinoid APIs enhances a lab’s credibility and reputation for quality and safety. This trust can attract partnerships with established pharmaceutical companies and foster long-term business relationships.
Differentiation from Competitors:
Being an early adopter of pharmaceutical standards can differentiate a lab from competitors who may still be operating under less stringent cannabis-specific regulations. Operational and Technological Advantages
Advanced Technology and Processes:
Transitioning to cannabinoid API manufacturing necessitates the adoption of advanced extraction and processing technologies, improving operational efficiency and product consistency. These technological advancements can also streamline processes, reduce costs, and maximize ROI and profitability in the long run.
Improved Facility Utilization:
Upgrading to meet pharmaceutical standards for cannabinoid API manufacturing can optimize facility use, ensuring that the lab operates at maximum efficiency, productivity, and profitability. PRO TIP Neither THC nor CBD are approved by the FDA as food or dietary supplement ingredients.
Both THC and CBD have been approved by the FDA for certain pharmaceutical applications. THC (dronabinol) is the active ingredient in the approved drug products, Marinol capsules (and generics) and Syndros oral solution. CBD is the active ingredient in the approved drug product, Epidiolex. Neither THC nor CBD are approved by the FDA as food or dietary supplement ingredients.
While the 2018 Farm Bill removed hemp (containing not more than 0.3% Delta-9 THC concentrate) from DEA regulation under the CSA (Controlled Substances Act), Hemp and CBD products remain subject to regulation under the Federal Food Drug & Cosmetic Act (FD&C Act) for drugs, foods, dietary supplements, cosmetics, and veterinary products.
TAKEAWAY: PHARMA is the FUTURE!! Regulatory Alignment and Compliance
Enhanced Regulatory Compliance:
Transitioning to pharmaceutical cannabinoid API manufacturing aligns with stricter regulatory standards, ensuring compliance with FDA and international guidelines, such as EudraLex Volume 4 GMP standards. This shift positions the lab to meet stringent quality control and safety requirements, which can lead to higher product quality and consumer trust.
Preemptive Compliance with Future Regulations:
By adopting pharmaceutical standards early, labs can stay ahead of future regulatory changes and avoid potential compliance issues as the cannabis industry evolves. Pivoting to cannabinoid API manufacturing as a licensed pharma lab positions you to avoid the precarious regulatory environment confronting state-licensed cannabis operations Strategic Positioning for Future Opportunities
Adaptability to Market Changes:
As the cannabis industry continues to evolve, being positioned as a pharmaceutical cannabinoid API manufacturer allows for greater adaptability to changing market demands and regulatory landscapes. This flexibility ensures the lab can pivot and innovate as needed to stay competitive.
Potential for Future Licensing and Expansion:
Successfully transitioning to cannabinoid API manufacturing can open doors for additional licensing opportunities and expansion into new product lines or therapeutic areas within the pharmaceutical industry. PRO TIP Botanically-derived Delta-9 THC has been approved for use in the United Kingdom since 2010.
Nabiximols (brand name Sativex in countries where it is approved) is a botanically derived oromucosal spray consisting of 2.7 mg of THC and 2.5 mg of CBD per spray. Nabiximols has been approved for the treatment of spasticity due to multiple sclerosis in the United Kingdom since June 2010. Conclusion
Converting a state-licensed cannabis extraction and processing lab to pharmaceutical API manufacturing offers numerous strategic advantages. From enhanced regulatory compliance and market expansion to increased credibility and operational efficiency, this transition positions the lab for long-term success and growth. As the DEA moves towards rescheduling cannabis to Schedule III, now is the opportune time to make this strategic pivot and capitalize on expanding and highly lucrative opportunities within the domestic and international pharmaceutical industry.
For further reading and sources:
FDA Guidance on Cannabis and Cannabis-Derived Products EudraLex Volume 4 GMP Guidelines DEA Rescheduling Information
KEY TAKEAWAY: Transitioning from crude extraction to API manufacturing isn't just a quality upgrade — it's a business model transformation that unlocks pharmaceutical pricing, regulatory exclusivity, and institutional partnerships.
KEY STAT: Market size, pricing, and margins vary substantially by product, jurisdiction, quality requirements, and commercial model; they should be assessed using current, named market sources.
KEY TAKEAWAY: Transitioning to API manufacturing requires FDA cGMP compliance, validated analytical methods, and equipment that meets ICH Q7 guidelines for active pharmaceutical ingredients.
Ready to Enter the API Manufacturing Space?
Prodigy's extraction systems are purpose-built for pharmaceutical-grade cannabinoid production. Our equipment is engineered with FDA cGMP, EU GMP EudraLex Volume 4, and ICH Q7 design and documentation considerations that may support an API project's equipment-planning process.